Presentation is loading. Please wait.

Presentation is loading. Please wait.

Mark A. Munger, PharmD, Przemyslaw Radwanski, PharmD, PhD, Greg C

Similar presentations


Presentation on theme: "Mark A. Munger, PharmD, Przemyslaw Radwanski, PharmD, PhD, Greg C"— Presentation transcript:

1 In vivo human time-exposure study of orally dosed commercial silver nanoparticles 
Mark A. Munger, PharmD, Przemyslaw Radwanski, PharmD, PhD, Greg C. Hadlock, PhD, Greg Stoddard, MS, Akram Shaaban, MD, Jonathan Falconer, BS, David W. Grainger, PhD, Cassandra E. Deering-Rice, PhD  Nanomedicine: Nanotechnology, Biology and Medicine  Volume 10, Issue 1, Pages 1-9 (January 2014) DOI: /j.nano Copyright © 2014 Elsevier Inc. Terms and Conditions

2 Figure 1 Optical absorbance spectrum of 32ppm commercial AgNPs measured on samples taken directly from the study stock bottle used in human oral ingestion and exposures (lot # 09280). Nanomedicine: Nanotechnology, Biology and Medicine  , 1-9DOI: ( /j.nano ) Copyright © 2014 Elsevier Inc. Terms and Conditions

3 Figure 2 Dynamic Light Scattering (DLS) particle size characterization of 32ppm commercial AgNPs as taken directly from commercial silver nanoparticle sample (lot # 09280). Nanomedicine: Nanotechnology, Biology and Medicine  , 1-9DOI: ( /j.nano ) Copyright © 2014 Elsevier Inc. Terms and Conditions

4 Nanomedicine: Nanotechnology, Biology and Medicine 2014 10, 1-9DOI: (10.1016/j.nano.2013.06.010)
Copyright © 2014 Elsevier Inc. Terms and Conditions


Download ppt "Mark A. Munger, PharmD, Przemyslaw Radwanski, PharmD, PhD, Greg C"

Similar presentations


Ads by Google